What I report today is the part one escalation. Escalation including a lot of tumor types, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer. And the number is limited, and with different dose ranges, from 50 milligrams to 320 milligrams. So when you do the subgroup analysis for those subtype patients, it’s really a very small number of patients in certain subtypes for certain cancer types malignancy...
What I report today is the part one escalation. Escalation including a lot of tumor types, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer. And the number is limited, and with different dose ranges, from 50 milligrams to 320 milligrams. So when you do the subgroup analysis for those subtype patients, it’s really a very small number of patients in certain subtypes for certain cancer types malignancy. So I couldn’t draw any conclusion of the activities in different subtypes. We can see the pre-clinical data released earlier last year in AACR 2025 and AACR 2026. It shows very promising anti-tumor activities in pre-clinical models in KRAS G12C, G12D, and G12V. But if we do a subgroup analysis in this trial for the escalation, it’s quite easy, quite early to jump to a conclusion. Maybe we can wait until future when we have more data in phase 1B expansion. We can have some clues.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
